ZELDIS JEROME B

Average Profitability
<0.0001%
Insider Buys Quantity
12
Insider Buys Sum
$210,882.96
Insider Sells Quantity
3
Insider Sells Sum
$2M

Insider Activity of ZELDIS JEROME B

According to the SEC Form 4 filings, ZELDIS JEROME B, being in a position of

  1. director at NEXGEL, Inc.,
    оver the last 12 months, has bought 13636 shares for $34,999, and sold 0 shares,
    over all time since 2022-03-25, has bought 23936 shares for $56,698, and sold 0 shares.

The largest purchase of all time was on 2021-02-17 and amounted to 5882 shares of NexImmune, Inc. for $99,994.

The largest sale of all time was on 2024-12-02 and amounted to 24000 shares of PTC Therapeutics, Inc. for $1.24M.

Biography of ZELDIS JEROME B

No biography is available at this moment.

2024-12-02SalePTC Therapeutics, Inc.
PTCT
director
24,000
0.0303%
$51.50$1.24M-7.7%
2024-11-20PurchaseNEXGEL, Inc.
NXGL
director
3,636
0.0323%
$2.75$9,999+7.27%
2024-08-23PurchaseNEXGEL, Inc.
NXGL
director
10,000
0.1028%
$2.50$25,000+11.15%
2024-05-22SalePTC Therapeutics, Inc.
PTCT
director
20,000
0.0258%
$38.24$764,800-5.08%
2023-05-26PurchaseNEXGEL, Inc.
NXGL
director
5,000
0.0914%
$2.34$11,689-2.62%
2022-03-25PurchaseNEXGEL, Inc.
NXGL
5,300
0.095%
$1.89$10,010-19.05%
2021-05-14SaleSoligenix, Inc.
SNGX
director
3,000
<0.0001%
$0.90$2,701+1.43%
2021-05-14PurchaseSoligenix, Inc.
SNGX
director
3,000
<0.0001%
$0.89$2,664+1.43%
2021-02-17PurchaseNexImmune, Inc.
NEXI
Executive VP of Research & Dev
5,882
0.0328%
$17.00$99,994-42.01%
2020-05-28PurchaseBioSig Technologies, Inc.
BSGM
director
1,000
0.004%
$10.49$10,489-51.67%
2019-11-19PurchaseSoligenix, Inc.
SNGX
director
2,000
0.0101%
$0.93$1,850+92.63%
2019-09-19PurchaseSoligenix, Inc.
SNGX
director
4,000
<0.0001%
$0.94$3,740+93.21%
2019-04-22PurchaseSoligenix, Inc.
SNGX
director
10,000
0.0002%
$0.73$7,274+47.89%
2015-12-23PurchaseSoligenix, Inc.
SNGX
director
2,500
<0.0001%
$1.27$3,175-36.84%
2013-06-25PurchaseSoligenix, Inc.
SNGX
director
23,809
0.0009%
$1.05$24,999+109.38%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.